Business Context and Reporting Period
Company: Anavex Life Sciences Corp.
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2009
Business Overview: Anavex is a development-stage biopharmaceutical company focused on discovering and developing novel drug targets for neurodegenerative diseases (Alzheimer's, epilepsy, depression) and cancer using its proprietary SIGMACEPTOR platform. The company has no commercial revenue and relies on financing to fund research and development (R&D). Its lead candidate, ANAVEX 2-73 (Alzheimer's), was preparing for Investigational New Drug (IND) filing with anticipated Phase 1 trials in early 2010.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Expenses | $4,739,602 | $5,281,213 |
| Net Loss | $(5,499,419) | $(5,351,269) |
| Cash and Cash Equivalents (End of Period) | $350,994 | $6,357 |
| Working Capital Deficit | $(3,691,514) | $(2,293,032) |
| Accumulated Deficit (Since Inception) | $(12,562,233) | $(7,062,814) |
| Current Liabilities | $4,098,466 | $2,299,389 |
| Promissory Notes Payable (Total) | $2,674,526 | $1,550,000 |
Note: The company reported a loss on extinguishment of debt of $487,469 and accretion of debt discount of $170,164 in 2009.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $541,611 (10.3%) compared to 2008. This was primarily driven by a $1.09 million decrease in consulting fees due to lower stock-based compensation charges and the elimination of rent and administration fees ($75,000) following the expiration of a Swiss lease.
- Increased R&D Spend: Research and development expenses increased by $660,312 (44.6%) to $2.14 million, reflecting continued investment in preclinical testing and IND preparation.
- Liquidity Improvement: Cash on hand increased significantly from $6,357 to $350,994, funded by private placements and the issuance of convertible promissory notes.
- Debt Expansion: Current liabilities increased by $1.8 million, largely due to the issuance of new promissory notes to fund operations.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Capital Needs
Management anticipates requiring approximately $10 million for the 12 months ending September 30, 2010, to fund clinical trials for ANAVEX 2-73, ANAVEX 1-41, and ANAVEX 7-1037. The company has no committed sources of financing and expects to rely on equity or debt offerings.
Going Concern Warning
The independent auditors have issued a report expressing substantial doubt about the company's ability to continue as a going concern due to the accumulated deficit and recurring losses. The financial statements do not include adjustments that might result from the outcome of this uncertainty.
Material Weaknesses in Internal Controls
Management concluded that disclosure controls and internal controls over financial reporting were not effective as of September 30, 2009. Identified weaknesses include:
- Insufficient segregation of duties due to limited personnel.
- Lack of sufficient supervision and review by management.
- Insufficient corporate governance policies and documentation.
- Lack of technical accounting knowledge regarding complex US GAAP matters.
Risk Factors
- Regulatory Risk: All drug candidates require extensive testing and FDA approval, which is uncertain and costly.
- Financing Risk: Failure to raise additional capital could force the company to delay or cease operations.
- Intellectual Property: The company relies on patents that may be challenged or may not provide adequate protection.
Investor Verification Checklist
- Capital Sufficiency: Verify if the company has secured the projected $10 million needed for 2010 operations, given the "substantial doubt" going concern warning.
- Debt Obligations: Review the terms of the $2.67 million in promissory notes, specifically the conversion features and maturity dates (many due in early 2010).
- Clinical Milestones: Confirm the status of the IND filing for ANAVEX 2-73 and the timeline for Phase 1 trials, as delays could impact funding needs.
- Internal Controls: Assess the progress of remediation plans for the identified material weaknesses in financial reporting.
- Dilution Risk: Monitor future equity issuances, as the company has a history of funding operations through stock sales and convertible notes, which dilutes existing shareholders.